Cargando…

Clinical study of treatment switching from premixed insulin to basal insulin combined with oral hypoglycemic drugs in patients with type 2 diabetes

AIM: Premixed insulin regimens are commonly used for the treatment of patients with type-2 diabetes mellitus (T2DM). However, limited data are available regarding next-step therapy options in cases where premixed insulin fails to provide adequate glycemic control. This 20-week observational study of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ying, Xie, Yi-juan, Meng, Dong-dong, Zhang, Hao-hang, Chen, Hui, Liu, En
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984683/ https://www.ncbi.nlm.nih.gov/pubmed/24620742 http://dx.doi.org/10.1186/1758-5996-6-37

Ejemplares similares

Combination Therapy With Premixed & Basal Insulin Analogues in Asian Indians With Type 2 Diabetes
por: Srivastava, Brijendra Kumar, et al.
Publicado: (2021)

Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
por: Moon, Shinje, et al.
Publicado: (2021)

Which Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study
por: Bu, Shi, et al.
Publicado: (2017)

The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy
por: Liu, Jhih-Syuan, et al.
Publicado: (2023)

Comparison of Basal-Bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes
por: Bellido, Virginia, et al.
Publicado: (2015)

Basal-bolus or premixed? Shedding light on optimal insulin regime for type 1 diabetes
por: Louise Walton, Emma
Publicado: (2018)

Transitioning from basal–bolus or premix insulin therapy to a combination of basal insulin and glucagon‐like peptide‐1 receptor agonist in people with type 2 diabetes
por: Mehta, Roopa, et al.
Publicado: (2022)

Practical Guidance on the Use of Premix Insulin Analogs in Initiating, Intensifying, or Switching Insulin Regimens in Type 2 Diabetes
por: Wu, Ted, et al.
Publicado: (2015)

Effects of basal and premixed insulin on glycemic control in type 2 diabetes patients based on multicenter prospective real‐world data
por: Peng, Ying, et al.
Publicado: (2022)

Basal-bolus Therapy in Patients with Type 2 Diabetes Mellitus in the UK: Patient Characteristics, Treatment Patterns and the Effect of Switching to Premixed Insulin
por: van Brunt, Kate, et al.
Publicado: (2016)

Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients
por: Harreiter, Jürgen, et al.
Publicado: (2017)

Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents: Basal or prandial insulin? The APOLLO trial and beyond
por: Bretzel, Reinhard G., et al.
Publicado: (2009)

Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine
por: Miao, Raymond, et al.
Publicado: (2013)

Effects of switching from prandial premixed insulin therapy to basal plus two times bolus insulin therapy on glycemic control and quality of life in patients with type 2 diabetes mellitus
por: Ito, Hiroyuki, et al.
Publicado: (2014)

Efficacy and Safety of Premixed Human Insulin Combined with Sulfonylureas in Type 2 Diabetic Patients Previously Poorly Controlled with Insulin
por: Chen, Ying-Hua, et al.
Publicado: (2019)

Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues
por: Vaag, Allan, et al.
Publicado: (2012)

Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs: When and for whom?
por: Mosenzon, Ofri, et al.
Publicado: (2013)

Unmet Needs in the Management of Type 2 Diabetes Mellitus Patients Starting Insulin Therapy with Basal or Premix Insulin in Routine Clinical Practice in Serbia
por: Beljić Živković, Teodora M., et al.
Publicado: (2018)

Comparison of the Effect of Glycemic Control in Type 2 Diabetes Outpatients Treated With Premixed and Basal Insulin Monotherapy in China
por: Liu, Guangxu, et al.
Publicado: (2018)

PSUN227 A retrospective comparison of Basal Bolus using Glargine U-300 and Glulisine with Premix Insulin
por: Abraham, Santhosh, et al.
Publicado: (2022)

Insulin and Oral Hypoglycemic Drug Overdose in Post-Mortem Investigations: A Literature Review
por: Manetti, Alice Chiara, et al.
Publicado: (2022)

Pharmacokinetics and pharmacodynamics of insulin glargine–insulin glulisine basal-bolus and twice-daily premixed analog insulin in type 1 diabetes mellitus patients during three standardized meals
por: Lamos, Elizabeth Mary, et al.
Publicado: (2015)

Metabolic Effects of Basal or Premixed Insulin Treatment in 5077 Insulin-Naïve Type 2 Diabetes Patients: Registry-Based Observational Study in Clinical Practice
por: Eliasson, Björn, et al.
Publicado: (2014)

Total costs of basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: register-based observational study in clinical practice
por: Svensson, Ann-Marie, et al.
Publicado: (2015)

Differential Treatment Response to Insulin Intensification Therapy: A Post Hoc Analysis of a Randomized Trial Comparing Premixed and Basal-Bolus Insulin Regimens
por: Shi, Li Xin, et al.
Publicado: (2017)

Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs
por: Baser, Onur, et al.
Publicado: (2013)

Titratable fixed‐ratio combination of basal insulin plus a glucagon‐like peptide‐1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes
por: Gomez‐Peralta, Fernando, et al.
Publicado: (2021)

Basal Insulin Reduces Glucose Variability and Hypoglycaemia Compared to Premixed Insulin in Type 2 Diabetes Patients: A Study Based on Continuous Glucose Monitoring Systems
por: Wang, Huiying, et al.
Publicado: (2022)

Comparison of Glycemic Variability and Hypoglycemic Events in Hospitalized Older Adults Treated with Basal Insulin plus Vildagliptin and Basal–Bolus Insulin Regimen: A Prospective Randomized Study
por: Batule, Sol, et al.
Publicado: (2022)

Comparison of Human Premixed and Basal Plus Short-Acting Insulin Regimens for Individuals With Type 2 Diabetes During Ramadan Fasting
por: Altemimi, Mahmood Thamer, et al.
Publicado: (2020)

THERAPY OF ENDOCRINE DISEASE: Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues
por: Vaag, Allan, et al.
Publicado: (2012)

Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US
por: Shao, Hui, et al.
Publicado: (2022)

Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs
por: Luo, Menghui, et al.
Publicado: (2020)

Expert Opinion: Patient Selection for Premixed Insulin Formulations in Diabetes Care
por: Kalra, Sanjay, et al.
Publicado: (2018)

Is There Evidence to Support Use of Premixed or Prandial Insulin Regimens in Insulin-Naive or Previously Insulin-Treated Type 2 Diabetic Patients?
por: Yki-Järvinen, Hannele, et al.
Publicado: (2013)

Characteristics Predictive for a Successful Switch from Insulin Analogue Therapy to Oral Hypoglycemic Agents in Patients with Type 2 Diabetes
por: Kim, Gyuri, et al.
Publicado: (2016)

Editorial: Non-insulin hypoglycemic drugs in type 2 diabetes remission
por: Guo, Kai-heng, et al.
Publicado: (2023)

Sexual Differences in response to Mid- or Low-Premixed Insulin Analogue in Patients with Type 2 Diabetes
por: Liu, Bing-li, et al.
Publicado: (2020)

Comparative assessment of the efficacy and safety of acarbose and metformin combined with premixed insulin in patients with type 2 diabetes mellitus
por: Wu, Honghua, et al.
Publicado: (2017)

Latent autoimmune diabetes of adults: From oral hypoglycemic agents to early insulin
por: Poudel, Resham R.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_a6mjhcf9kjopbde2db2k92pccr